Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Godugu, Chandraiah ^a   Patel, Apurva R ^a   Doddapaneni, Ravi ^a   Somagoni, Jaganmohan ^a   Singh, Mandip ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BERBERINE; BETULIC ACID; CASPASE 3; CASPASE 8; CD31 ANTIGEN; CYCLIN D1; GA 30024; GELATINASE B; HYDROXYPROPYLMETHYLCELLULOSE; HYPOXIA INDUCIBLE FACTOR 1; MA 01835; NEW DRUG; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; SURVIVIN; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; TRITERPENE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DOWN REGULATION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG PENETRATION; DUAL CHANNEL SPRAY GUN TECHNOLOGY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE CELL; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MONOLAYER CULTURE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; RAT MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAY DRIED MUCOADHESIVE FORMULATION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BIOAVAILABILITY; CELL CLONE; CELL DEATH; CELL MEMBRANE PERMEABILITY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MEDICINAL CHEMISTRY; METABOLISM; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; SPRAGUE DAWLEY RAT; TUMOR CELL LINE; TUNEL ASSAY; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BERBERINE; BIOLOGICAL AVAILABILITY; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CHEMISTRY, PHARMACEUTICAL; CLONE CELLS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LUNG NEOPLASMS; MICE, NUDE; RATS, SPRAGUE-DAWLEY; TRITERPENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84897484868     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089919     Document Type: Article

References (51)

1. Mullauer FB, Kessler JH, Medema JP (2010) Betulinic acid, a natural compound with potent anticancer effects. Anticancer Drugs 21: 215-227.
2. Farnsworth NR, Akerele O, Bingel AS, Soejarto DD, Guo Z (1985) Medicinal plants in therapy. Bull World Health Organ 63: 965-981. (Pubitemid 16055431)
3. Subbaiah TV, Amin AH (1967) Effect of berberine sulphate on Entamoeba histolytica. Nature 215: 527-528.
4. Ho YT, Yang JS, Lu CC, Chiang JH, Li TC, et al. (2009) Berberine inhibits human tongue squamous carcinoma cancer tumor growth in a murine xenograft model. Phytomedicine 16: 887-890.
5. Abd El-Wahab AE, Ghareeb DA, Sarhan EE, Abu-Serie MM, El Demellawy MA (2013) In vitro biological assessment of berberis vulgaris and its active constituent, berberine: antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects. BMC Complement Altern Med 13: 218.
6. Hwang JM, Wang CJ, Chou FP, Tseng TH, Hsieh YS, et al. (2002) Inhibitory effect of berberine on tert-butyl hydroperoxide-induced oxidative damage in rat liver. Arch Toxicol 76: 664-670.
7. Kong W, Wei J, Abidi P, Lin M, Inaba S, et al. (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10: 1344-1351. (Pubitemid 40022716)
8. Zhang H, Wei J, Xue R, Wu JD, Zhao W, et al. (2010) Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 59: 285-292.
9. Kuo CL, Chi CW, Liu TY (2004) The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 203: 127-137.
10. Zhang Y, Li X, Zou D, Liu W, Yang J, et al. (2008) Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 93: 2559-2565. (Pubitemid 352008520)
11. Yang X, Yang B, Cai J, Zhang C, Zhang Q, et al. (2013) Berberine enhances radiosensitivity of esophageal squamous cancer by targeting HIF-1alpha in vitro and in vivo. Cancer Biol Ther 14.
12. Pandey MK, Sung B, Aggarwal BB (2010) Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int J Cancer 127: 282-292.
13. Chen Z, Wu Q, Chen Y, He J (2008) Effects of betulinic acid on proliferation and apoptosis in Jurkat cells and its in vitro mechanism. J Huazhong Univ Sci Technolog Med Sci 28: 634-638.
14. Gheorgheosu D, Jung M, Oren B, Schmid T, Dehelean C, et al. (2013) Betulinic acid suppresses NGAL-induced epithelial-to-mesenchymal transition in melanoma. Biol Chem 394: 773-781.
15. Shin J, Lee HJ, Jung DB, Jung JH, Lee HJ, et al. (2011) Suppression of STAT3 and HIF-1 alpha mediates anti-angiogenic activity of betulinic acid in hypoxic PC-3 prostate cancer cells. PLoS One 6: e21492.
16. Bache M, Zschornak MP, Passin S, Kessler J, Wichmann H, et al. (2011) Increased betulinic acid induced cytotoxicity and radiosensitivity in glioma cells under hypoxic conditions. Radiat Oncol 6: 111.
17. Mullauer FB, van Bloois L, Daalhuisen JB, Ten Brink MS, Storm G, et al. (2011) Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity. Anticancer Drugs 22: 223-233.
18. Cheng Z, Chen AF, Wu F, Sheng L, Zhang HK, et al. (2010) 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models. Bioorg Med Chem 18: 5915-5924.
19. Wang SD, Song BS, Li K (2000) [Determination of berberine in decocted liquid from shenshu granules with water by reversed-phase liquid chromatography]. Se Pu 18: 261-262.
20. Hua W, Ding L, Chen Y, Gong B, He J, et al. (2007) Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharm Biomed Anal 44: 931-937. (Pubitemid 47095187)
21. Zuo F, Nakamura N, Akao T, Hattori M (2006) Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry. Drug Metab Dispos 34: 2064-2072. (Pubitemid 44837767)
22. Liu YT, Hao HP, Xie HG, Lai L, Wang Q, et al. (2010) Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos 38: 1779-1784.
23. Chen CM, Chang HC (1995) Determination of berberine in plasma, urine and bile by high-performance liquid chromatography. J Chromatogr B Biomed Appl 665: 117-123.
24. Liu Y, Hao H, Xie H, Lv H, Liu C, et al. (2009) Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats. J Pharm Sci 98: 4391-4401.
25. Hu Y, Ehli EA, Kittelsrud J, Ronan PJ, Munger K, et al. (2012) Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine 19: 861-867.
26. Yin J, Xing H, Ye J (2008) Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57: 712-717. (Pubitemid 351608234)
27. Fan D, Wu X, Dong W, Sun W, Li J, et al. (2013) Enhancement by sodium caprate and sodium deoxycholate of the gastrointestinal absorption of berberine chloride in rats. Drug Dev Ind Pharm 39: 1447-1456.
28. Sun YF, Song CK, Viernstein H, Unger F, Liang ZS (2013) Apoptosis of human breast cancer cells induced by microencapsulated betulinic acid from sour jujube fruits through the mitochondria transduction pathway. Food Chem 138: 1998-2007.
29. Dehelean CA, Feflea S, Ganta S, Amiji M (2011) Anti-angiogenic effects of betulinic acid administered in nanoemulsion formulation using chorioallantoic membrane assay. J Biomed Nanotechnol 7: 317-324.
30. Godugu C, Patel AR, Doddapaneni R, Marepally S, Jackson T, et al. (2013) Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J Control Release 172: 86-95.
31. Godugu C, Patel AR, Desai U, Andey T, Sams A, et al. (2013) AlgiMatrix based 3D cell culture system as an in-vitro tumor model for anticancer studies. PLoS One 8: e53708.
32. Patel MSaAR (2011) Dual channel spray dried modified multi-layered microstructures for oral delivery. US Provisional Patent Application # 61/440,977.
33. Lu WB, Chen WW, Li RL (2010) [Determination of berberine chloride in mouse plasma after intragastric administration of Lianxiang microemulsion]. Zhong Yao Cai 33: 957-960.
34. Wang T, Wang N, Song H, Xi X, Wang J, et al. (2011) Preparation of an anhydrous reverse micelle delivery system to enhance oral bioavailability and anti-diabetic efficacy of berberine. Eur J Pharm Sci 44: 127-135.
35. Ma X, Zhou J, Zhang CX, Li XY, Li N, et al. (2013) Modulation of drugresistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes. Biomaterials 34: 4452-4465.
36. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, et al. (2006) Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55: 2256-2264. (Pubitemid 44743622)
37. Willmann M, Wacheck V, Buckley J, Nagy K, Thalhammer J, et al. (2009) Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound. Eur J Clin Invest 39: 384-394.
38. Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, et al. (1995) Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1: 1046-1051.
39. Fulda S, Kroemer G (2009) Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov Today 14: 885-890.
40. Liu X, Jutooru I, Lei P, Kim K, Lee SO, et al. (2012) Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer. Mol Cancer Ther 11: 1421-1431.
41. Xu H, Ren X, Du Y, Zhang L, Li T, et al. (2012) [Study on absorption kinetics of betulic acid in rat's intestines]. Zhongguo Zhong Yao Za Zhi 37: 377-380.
42. Zhang Y, Cui YL, Gao LN, Jiang HL (2013) Effects of beta-cyclodextrin on the intestinal absorption of berberine hydrochloride, a P-glycoprotein substrate. Int J Biol Macromol 59: 363-371.
43. Holmes EH, Devalapally H, Li L, Perdue ML, Ostrander GK (2013) Permeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatment. PLoS One 8: e61853.
44. Gupta PK, Hubbard M, Gurley B, Hendrickson HP (2009) Validation of a liquid chromatography-tandem mass spectrometric assay for the quantitative determination of hydrastine and berberine in human serum. J Pharm Biomed Anal 49: 1021-1026.
45. Chen W, Fan D, Meng L, Miao Y, Yang S, et al. (2012) Enhancing effects of chitosan and chitosan hydrochloride on intestinal absorption of berberine in rats. Drug Dev Ind Pharm 38: 104-110.
46. Xu LN, Lu BN, Hu MM, Xu YW, Han X, et al. (2012) Mechanisms involved in the cytotoxic effects of berberine on human colon cancer HCT-8 cells. Biocell 36: 113-120.
47. Fu L, Chen W, Guo W, Wang J, Tian Y, et al. (2013) Berberine Targets AP-2/hTERT, NF-kappaB/COX-2, HIF-1alpha/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth. PLoS One 8: e69240.
48. Kuo HP, Chuang TC, Tsai SC, Tseng HH, Hsu SC, et al. (2012) Berberine, an isoquinoline alkaloid, inhibits the metastatic potential of breast cancer cells via Akt pathway modulation. J Agric Food Chem 60: 9649-9658.
49. Tan Y, Yu R, Pezzuto JM (2003) Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. Clin Cancer Res 9: 2866-2875. (Pubitemid 36842133)
50. Zeng XH, Zeng XJ, Li YY (2003) Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 92: 173-176.
51. Diogo CV, Machado NG, Barbosa IA, Serafim TL, Burgeiro A, et al. (2011) Berberine as a promising safe anti-cancer agent - is there a role for mitochondria? Curr Drug Targets 12: 850-859.